Terms: = Lung cancer AND CgA AND Staging
10 results:
1. Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring lung Well-Differentiated Neuroendocrine Tumors: A Brief Report.
Nisman B; Oleinikov K; Nechushtan H; Maimon O; Atlan K; Peled N; Gross D; Peretz T; Meirovitz A; Grozinsky-Glasberg S
J Thorac Oncol; 2023 Mar; 18(3):369-376. PubMed ID: 36503175
[TBL] [Abstract] [Full Text] [Related]
2. [On detection of chromogranin A, synaptophysin, neuronspecific enolase and progastrin-releasing peptide in small cell lung cancer].
Lu QQ; Li J; Li YH; Liu H; Xie XB
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jul; 56(7):1017-1022. PubMed ID: 35899358
[TBL] [Abstract] [Full Text] [Related]
3. Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.
Ni J; Zhang X; Wang H; Si X; Xu Y; Zhao J; Chen M; Zhang L; Wang M
Thorac Cancer; 2022 Feb; 13(4):539-548. PubMed ID: 34970848
[TBL] [Abstract] [Full Text] [Related]
4. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract] [Full Text] [Related]
5. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.
Hörsch D; Schmid KW; Anlauf M; Darwiche K; Denecke T; Baum RP; Spitzweg C; Grohé C; Presselt N; Stremmel C; Heigener DF; Serke M; Kegel T; Pavel M; Waller CF; Deppermann KM; Arnold R; Huber RM; Weber MM; Hoffmann H
Oncol Res Treat; 2014; 37(5):266-76. PubMed ID: 24853787
[TBL] [Abstract] [Full Text] [Related]
6. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer.
Petrović M; Bukumirić Z; Zdravković V; Mitrović S; Atkinson HD; Jurišić V
Med Oncol; 2014 Feb; 31(2):823. PubMed ID: 24375395
[TBL] [Abstract] [Full Text] [Related]
7. Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoids.
Telega A; Kos-Kudła B; Foltyn W; Blicharz-Dorniak J; Rosiek V
Endokrynol Pol; 2012; 63(6):477-82. PubMed ID: 23339006
[TBL] [Abstract] [Full Text] [Related]
8. Chromogranin A--serum marker for prostate cancer.
Khan MO; Ather MH
J Pak Med Assoc; 2011 Jan; 61(1):108-11. PubMed ID: 22368921
[TBL] [Abstract] [Full Text] [Related]
9. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract] [Full Text] [Related]
10. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase.
Giovanella L; Ceriani L; Bandera M; Garancini S
Int J Biol Markers; 2001; 16(1):50-5. PubMed ID: 11288956
[TBL] [Abstract] [Full Text] [Related]
